EATG » Effectiveness of sofosbuvir-containing regimens for hepatitis C, HIV

Effectiveness of sofosbuvir-containing regimens for hepatitis C, HIV

For patients coinfected with chronic hepatitis C and HIV, treatment regimens containing sofosbuvir are effective but come with a significant risk for adverse effects, according to a meta-analysis published in Virology Journal.

The researchers included 7 studies (n=1167 coinfected patients) in their analysis. They included clinical trials, case-control studies, and prospective cohort studies that assessed the efficacy and safety of sofosbuvir-containing regimens in patients coinfected with hepatitis C and HIV. The researchers searched PubMed Medline, EMBASE, and Cochrane databases to find eligible studies.

Of the 1167 coinfected patients, the researchers found that 94% (95% CI, 92%-95%) had a sustained virologic response at 12 weeks. Treatment-naive patients had a higher rate of sustained virologic response at 12 weeks compared with patients who had been treated previously (P <.01).

Despite the high rate of efficacy of sofosbuvir-containing regimens, the researchers found that 79.6% (95% CI, 77.1%-82.1%) of patients treated with these regimens experienced adverse events, with 2.8% (95% CI, 1.4%-4.3%) experiencing severe adverse events. The most common adverse events were fatigue, insomnia, asthenia, headache, diarrhea, and nausea.

The researchers noted that patients treated with sofosbuvir combined with other direct-acting antivirals had a higher likelihood of sustained virologic response at 12 weeks and a reduced rate of adverse events compared with patients treated with sofosbuvir and ribavirin.

By Hannah Dellabella

Reference

Li G, Zang K, Zhang G, Zhu D, Deng X. Efficacy and safety of sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis. Virol J. 2018;15(1):19.

Source:
Infectious Disease Advisor
News categories: Hepatitis